Target Audience
This activity is intended for gastroenterologists and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.
|
|
|
Statement of Need
Inflammatory bowel disease (IBD) consists of two chief sub-conditions (Crohn’s disease and ulcerative colitis) which are chronic, systemic, autoimmune disorders characterized by inflammatory processes in the digestive tract. These conditions are often lifelong, chronic conditions without a medical cure and commonly require a lifetime of care. While there are multiple classes of therapies available to treat IBD, and some patients achieve low disease activity or remission, a significant proportion of IBD patients exhibit an inadequate response to therapy. Clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD. Furthermore, awareness of potential adverse events associated with this new class of therapies and potential mitigation strategies are also needed.
The increasing availability of these novel agents complicates treatment decisions for IBD. Therapy selection decisions should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. Gastroenterologists need to enhance their understanding of novel targets and best practices in order to manage their patient populations effectively.
|
|
|
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of IBD
- Compare and contrast the cytokine pathways targeted by JAK inhibitors under investigation for IBD
- Interpret the clinical trial efficacy and safety data of available and emerging JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
- Identify IBD patients who may require a change in therapy due to lack or loss of response
|
|
|
How to Receive Credit
To receive credit, participants are required to participate in the live activity, complete the posttest and evaluation and submit on-site. A certificate will be emailed to participants within 6 weeks. There is no fee to participate in the activity or for the generation of the certificate. Please be sure to check your spam/junk folders, as certificates sometimes are sent to those folders.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
|
|
|
Accreditation and Credit Designation
|
 |
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
|
|
The ACHL designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.
|
|
|
|
Disclosure Information
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity. Complete information will be provided to participants prior to the start of the educational activity.
Supported by an educational grant from Gilead Sciences, Inc.
|
